Top-line Phase 2 data for phenylketonuria (PKU) demonstrated robust plasma Phe reduction and high response rate; Phase 3 study initiation planned for H1 2023
Clinical readouts for SYNB1353 for homocystinuria (HCU) and SYNB8802 for enteric hyperoxaluria (EH) expected in 2022
$91.7 million in cash, cash equivalents and short-term investments support projected runway into 2024
CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today reported financial results for the third quarter ended September 30, 2022 and provided an update on its pipeline programs.
“We’re thrilled with the recently announced results of our Phase 2 Synpheny-1 study in phenylketonuria (PKU), which demonstrates the potential to provide a transformative treatment option for patients,” said Aoife Brennan, M.B. Ch.B, Synlogic President and Chief Executive Officer. “These data also validate our platform and approach to drug development, and we are looking forward to additional readouts from our programs for homocystinuria (HCU) and enteric hyperoxaluria (EH) later this year.”
Anticipated Upcoming Milestones
- Initiate the Phase 3 trial for SYNB1934 in PKU in H1 2023 with Phase 3 readiness activities currently underway.
- Share data from the Phase 1 trial in healthy volunteers for SYNB1353 for HCU in 2022.
- Share proof of concept data for SYNB8802 for EH in 2022.
Recent Business Highlights
- Announced positive top-line data from the Phase 2 Synpheny-1 study of SYNB1934 and SYNB1618 in PKU.
- Confirmed that SYNB1934 will progress to the Phase 3 registrational study expected to begin in H1 2023.
- Earned a research milestone for the achievement of prespecified success criteria under the research collaboration agreement with Roche for the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease (IBD).
Third Quarter 2022 Financial Results
As of September 30, 2022, Synlogic had cash, cash equivalents and short-term investments of $91.7 million.
Revenue for the three months ended September 30, 2022 was $0.7 million compared to $0.9 million for the corresponding period in 2021. Revenue in both periods was associated with the ongoing research collaboration with Roche for the discovery of a novel Synthetic Biotic for the treatment of IBD.
For the three months ended September 30, 2022, Synlogic reported a consolidated net loss of $17.9 million, or $0.25 per share, compared to a consolidated net loss of $16.0 million, or $0.29 per share, for the corresponding period in 2021.
Research and development expenses were $14.6 million for the three months ended September 30, 2022 compared to $13.4 million for the corresponding period in 2021.
General and administrative expenses were $4.4 million for the three months ended September 30, 2022 compared to $3.6 million for the corresponding period in 2021.
Financial Outlook
Based upon its current operating plan and balance sheet as of September 30, 2022, Synlogic expects to have sufficient cash to be able to fund operations into 2024.
About Synlogic
Synlogic is a clinical-stage biotechnology company developing medicines through its proprietary approach to synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the first half of 2023, and additional novel drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic’s reproducible, target-specific drug design. Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunological diseases. In addition to its clinical programs, Synlogic has a research collaboration with Roche on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease (IBD). Synlogic has also developed two drug candidates through a research collaboration with Ginkgo Bioworks: SYNB1353, designed to consume methionine for the potential treatment of HCU, and SYNB2081, designed to lower uric acid for the potential treatment of gout. For additional information visit www.synlogictx.com.
Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," “look forward,” "estimate," "expect," "intend," on track,” "plan," "predict" and similar expressions and their variants, as they relate to Synlogic, may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's approach to Synthetic Biotics to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism and inflammatory and immune disorders; our expectations about sufficiency of our existing cash balance; the future clinical development of Synthetic Biotics; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; and the expected timing of Synlogic's clinical trials of SYNB1618, SYNB1934, SYNB1353, SYNB8802 and SYNB2081 and availability of clinical trial data. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" in Synlogic's filings with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.
| Synlogic, Inc. | ||||||||||||||||
| Condensed Consolidated Statements of Operations | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| (in thousands except share and per share data) | For the Three Months Ended | For the Nine Months Ended | ||||||||||||||
| September 30, 2022 | September 30, 2021 | September 30, 2022 | September 30, 2021 | |||||||||||||
| Revenue | $ | 678 | $ | 916 | $ | 1,074 | $ | 1,162 | ||||||||
| Operating expenses | ||||||||||||||||
| Research and development | 14,610 | 13,355 | 38,405 | 35,254 | ||||||||||||
| General and administrative | 4,402 | 3,616 | 12,785 | 11,528 | ||||||||||||
| Total operating expenses | 19,012 | 16,971 | 51,190 | 46,782 | ||||||||||||
| Loss from operations | (18,334 | ) | (16,055 | ) | (50,116 | ) | (45,620 | ) | ||||||||
| Other income, net | 422 | 39 | 665 | 148 | ||||||||||||
| Net loss | $ | (17,912 | ) | $ | (16,016 | ) | $ | (49,451 | ) | $ | (45,472 | ) | ||||
| Net loss per share - basic and diluted | $ | (0.25 | ) | $ | (0.29 | ) | $ | (0.69 | ) | $ | (0.91 | ) | ||||
| Weighted-average common shares used in computing net loss per share - basic and diluted | 72,108,113 | 55,336,936 | 72,061,935 | 49,730,231 | ||||||||||||
| Synlogic, Inc. | ||||||
| Condensed Consolidated Balance Sheets | ||||||
| (unaudited) | ||||||
| (in thousands, except share data) | ||||||
| September 30, 2022 | December 31, 2021 | |||||
| Assets | ||||||
| Cash, cash equivalents, & marketable securities | $ | 91,656 | $ | 136,629 | ||
| Property and equipment, net | 7,901 | 9,088 | ||||
| Other assets | 28,680 | 29,019 | ||||
| Total assets | $ | 128,237 | $ | 174,736 | ||
| Liabilities and stockholders' equity | ||||||
| Current liabilities | $ | 11,602 | $ | 10,080 | ||
| Long-term liabilities | 16,207 | 17,390 | ||||
| Total liabilities | 27,809 | 27,470 | ||||
| Total stockholders' equity | 100,428 | 147,266 | ||||
| Total liabilities and stockholders' equity | $ | 128,237 | $ | 174,736 | ||
| Common stock and common stock equivalents | ||||||
| Common stock | 70,285,495 | 69,698,844 | ||||
| Common stock warrants (pre-funded) | 2,548,117 | 2,548,117 | ||||
| Total common stock | 72,833,612 | 72,246,961 | ||||
| MEDIA CONTACT: | INVESTOR CONTACT: |
| Bill Berry Berry & Company Public Relations Phone: 212-253-8881 Email: bberry@berrypr.com | Andrew Funderburk Kendall Investor Relations Phone: 617-401-9152 Email: afunderburk@kendallir.com |
